- Home
- SERA
as 11-14-2025 9:48am EST
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 90.6M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 41.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.37 - $9.13 | Next Earning Date: | 11-13-2025 |
| Revenue: | $95,000 | Revenue Growth: | 1.06% |
| Revenue Growth (this year): | 217.92% | Revenue Growth (next year): | 479.25% |
Stock Insider Trading Activity of Sera Prognostics Inc. (SERA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Boniface John J. | SERA | Chief Scientific Officer | Nov 10 '25 | Sell | $2.62 | 7,767 | $20,349.54 | 151,726 | |
| Lindgardt Zhenya | SERA | Chief Executive Officer | Nov 10 '25 | Sell | $2.62 | 11,594 | $30,376.28 | 796,296 | |
| Kearney Paul | SERA | Chief Data Officer | Nov 10 '25 | Sell | $2.62 | 7,073 | $18,531.26 | 168,596 | |
| Jackson Benjamin | SERA | General Counsel | Nov 10 '25 | Sell | $2.62 | 7,059 | $18,494.58 | 119,758 | |
| Aerts Austin | SERA | Chief Financial Officer | Nov 10 '25 | Sell | $2.62 | 6,351 | $16,639.62 | 278,319 | |
| Harrison Robert Gardner | SERA | Chief Information Officer | Nov 10 '25 | Sell | $2.62 | 6,528 | $17,103.36 | 89,404 | |
| Mirza Mansoor Raza | SERA | Director | Nov 5 '25 | Sell | $3.04 | 221 | $671.84 | 58,032 | |
| Harrison Robert Gardner | SERA | Chief Information Officer | Nov 4 '25 | Sell | $3.07 | 2,000 | $6,140.00 | 89,404 | |
| Harrison Robert Gardner | SERA | Chief Information Officer | Oct 7 '25 | Sell | $3.18 | 2,000 | $6,360.00 | 89,404 | |
| Mirza Mansoor Raza | SERA | Director | Oct 6 '25 | Sell | $3.16 | 227 | $717.32 | 58,032 |
Latest Sera Prognostics Inc. News
SERA Breaking Stock News: Dive into SERA Ticker-Specific Updates for Smart Investing
GuruFocus.com
2 days ago
Sera Prognostics Inc (SERA) Q3 2025 Earnings Call Highlights: Strategic Medicaid Pilots and ...
Zacks
2 days ago
Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Misses Revenue Estimates
PR Newswire
2 days ago
SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
Zacks
11 days ago
Premier, Inc. (PINC) Tops Q1 Earnings and Revenue Estimates
PR Newswire
16 days ago
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS ON NOVEMBER 13, 2025
Simply Wall St.
5 months ago
We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully
Investopedia
6 months ago
Ulta Stock Jumps as Beauty Product Spending Continues
GlobeNewswire
6 months ago
Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy
Compare SERA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SERA Sera Prognostics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.